XML 67 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Note 12 - Segment Information - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues $ 53,165 $ 58,749 $ 103,810 $ 109,202 $ 103,810 $ 109,202
Gross profit (loss) 32,109 36,386     63,292 67,727
Operating expense 32,169 32,391     64,016 68,326
Operating (loss) income (60) 3,995     (724) (599)
Nonoperating expense, net (1,265) (611)     (1,538) (1,429)
Operating Segments [Member]            
Gross profit (loss) 32,119 36,404     63,302 67,762
Operating expense 32,169 32,391     64,016 68,326
Operating (loss) income (60) 3,995     (724) (599)
Nonoperating expense, net 1,265 611     1,538 1,429
(Loss) earnings before income taxes (1,325) 3,384     (2,262) (2,028)
Operating Segments [Member] | Sterilization and Disinfection Control [Member]            
Revenues 17,080 [1] 16,964 [1] 33,007 31,738 33,007 [1] 31,738 [1]
Gross profit (loss) 12,476 12,199     24,067 22,967
Operating Segments [Member] | Clinical Genomics [Member]            
Revenues 15,549 [1] 18,435 [1] 28,918 32,940 28,918 [1] 32,940 [1]
Gross profit (loss) 7,727 10,641     14,455 18,490
Operating Segments [Member] | Biopharmaceutical Development [Member]            
Revenues 9,207 [1] 12,144 [1] 19,096 23,111 19,096 [1] 23,111 [1]
Gross profit (loss) 5,509 7,557     11,942 14,634
Operating Segments [Member] | Calibration Solutions [Member]            
Revenues 11,329 [1],[2] 11,206 [1],[2] $ 22,789 [2] $ 21,413 [2] 22,789 [1] 21,413 [1]
Gross profit (loss) 6,407 6,007     12,838 11,671
Corporate, Non-Segment [Member]            
Revenues [1],[3] $ (10) $ (18)     $ (10) $ (35)
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.
[3] Unallocated corporate expenses and other business activities are reported within Corporate and Other.